Hereditary Tyrosinemia - Pathogenesis, Screening and Management (Hardcover, 1st ed. 2017)

Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH). The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800). The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.

General

Imprint:	Springer International Publishing AG
Country of origin:	Switzerland
Series:	Advances in Experimental Medicine and Biology, 959
Release date:	August 2017
First published:	2017
Editors:	Robert M. Tanguay
Dimensions:	254 x 178mm (L x W)
Format:	Hardcover
Pages:	247
Edition:	1st ed. 2017
ISBN-13:	978-3-319-55779-3
Categories:	Books > Science & Mathematics > Biology, life sciences > Biochemistry > Proteins Promotions
LSN:	3-319-55779-3
Barcode:	9783319557793

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!